Home
About Us
Company Profile
HIstory
Culture
Honor
Products
Cardiovascular series
Psychiatry series
Hepatobiliary, Gastroenterology Series
Respiratory series
Anti-infective virus series
Other series
Large Infusion Series
Huabao Tong Series
Active Pharmaceutical Ingredient Series
R&D
Academician Expert Workstation
Medical Research and Industry Alliance
News
General News
Party group dynamics
Employee activity
HR
Talent Strategy
Company recruitment
Contact us
中文版
2025/04/15
Good News | Warm Congratulations to Wanbande Pharmaceutical Group Co., Ltd. (Registered Trademark: wepon), which has been honored with the third batch of the "Taizhou Time-Honored Brand" title!
2025/04/14
New peptide candidate compound: Preclinical studies in the metabolic field show promising progress.
[“Station” Success Report] | Wanbangde Pharmaceutical Group’s Postdoctoral Research Workstation Gains New Talent, Accelerating the Advancement of Innovative Drug Development!
Mingjie Pharma's inaugural national CMC pharmacy salon tour for 2025 concludes successfully | Wanbangde Pharmaceutical deeply engages in technical exchanges
Good News | Maband Pharmaceutical Group's Mecobalamin Granted Orphan Drug Designation by the U.S. FDA for the Treatment of ALS
[Another Milestone: Wanbangde Pharmaceutical Group's Huperzine A Injection Included in the "Clinical Guidelines for Rational Drug Use in Cerebrovascular Diseases"]
2025/01/21
Good News | Wanbangde Pharmaceutical Group's WP103 (Huperzine A Injection) Receives U.S. FDA Approval for Clinical Trials
Good News | Wanbangde Pharmaceutical Group’s WP107 (Huperzine A Oral Solution) Receives U.S. FDA Approval for Clinical Trials
2025/01/13
Good News | Wanbangde Pharmaceutical Group's Cefaclor Granules Pass Consistency Evaluation!
2025/01/08
2024
2024/12/30
News | The Annual Meeting of Wanbande Pharmaceutical Group's Academician and Expert Workstation Successfully Held
For three consecutive years, Wanbande Pharmaceutical Group has been recognized among the Top 500 High-Tech Enterprises in Zhejiang Province for Innovation Capability!
Wanbangde achieves another breakthrough in innovative drug development—WP103 holds the potential to address the critical clinical need for treating neonatal HIE! This globally rare FDA dual-designated drug has once again received IND application acceptance.
2024/12/16
Wandet Pharmaceutical Group's WP107 (Huperzine A Oral Solution) clinical trial application has been accepted by the U.S. FDA!
Walking through the millennia-old cave complex, spreading the power of philanthropy | Wanbangde Pharmaceutical Group’s “Love Walk” event concludes successfully!
